Pharmaceuticals News and Research

RSS

Simulations Plus second quarter net sales increase 6.4% to $2.789M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2012 ended February 29, 2012.

11 Apr 2012

Oxytocin may offer hope for male sexual dysfunction

The hormone oxytocin that is also called the “love hormone” since it plays a role in the bond between a mother and baby may also improve sexual function - at least in men with Asperger’s syndrome - according to a published case report.

10 Apr 2012

Genstar Capital enters definitive agreement to acquire ERT

eResearchTechnology, Inc. (ERT), a global technology-driven provider of health outcomes research services to biopharmaceutical sponsors and contract research organizations (CROs), today announced that it has entered into a definitive agreement to be acquired by affiliates of Genstar Capital LLC, a leading middle market private equity firm for $8.00 per share in cash in a transaction valued at approximately $400 million.

10 Apr 2012

Akorn launches generic Vancocin for treatment of CDAD

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma's Vancocin, which is indicated for the treatment of Clostridium difficile-associated diarrhea.

10 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee's Pharma.

10 Apr 2012

Canon, MEDIAN to demonstrate LMS clinical application portfolio at ITEM

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions -LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.

10 Apr 2012

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

10 Apr 2012

Affiliate of Sun Capital acquires CornerStone

Sun Capital Partners, Inc., a leading private investment firm specializing in leveraged buyouts and investments in market-leading companies, today announced that an affiliate has acquired CornerStone Research & Development, Inc., a leading global contract manufacturer of top-branded vitamins and dietary supplements, from Mitsui & Co. (U.S.A.), Inc.

10 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

TherapeuticsMD introduces second prescription prenatal vitamin

TherapeuticsMD, Inc., parent company of vitaMedMD, LLC, a specialty pharmaceutical company, announced that on April 9, 2012 it launched its second prescription prenatal vitamin, vitaMedMD One Rx, following the successful launch of vitaMedMD Plus Rx last month.

9 Apr 2012

Medutech to market ETView's VivaSight airway management platform

ETView Medical, Ltd. announced today that it has entered into a distribution agreement with Medutech Co., Ltd..

9 Apr 2012

Bioness commences StimRouter Neuromodulation System study for chronic peripheral nerve pain

Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.

9 Apr 2012

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc.,, announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve.

9 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Derma Sciences closes underwritten registered direct offering

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that it closed an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share on April 5, 2012.

9 Apr 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

Pacira launches EXPAREL in the U.S.

Pacira Pharmaceuticals, Inc. today announced the commercial launch of EXPAREL (bupivacaine liposome injectable suspension) in the United States. Starting today, EXPAREL will begin shipping to hospital and ambulatory care customers through their normal wholesaler and distributor channels.

9 Apr 2012

KU researchers receive inventorship credit on NIH-owned Velcade patents

Pillsbury today announced that its clients, the University of Kansas and the University of Kansas Center for Research, Inc., a nonprofit corporation affiliated with KU, prevailed in a closely watched legal battle over cancer drug formulation patents after an arbitration panel ruled in KUCR's favor following years of litigation against the National Institutes of Health.

7 Apr 2012

UNC implements Lawson Human Capital Management solution

Until December, 2011, UNC Health Care System relied upon a legacy Human Resources system that was not designed for the healthcare industry. And this mismatch created problems that necessitated awkward, albeit creative, workarounds. But now, thanks to CIBER partnering with UNC to implement the Lawson Human Capital Management (HCM) solution, they are responsive and agile, especially in terms of reporting and employee issues.

7 Apr 2012